1. (valid email required)
 

cforms contact form by delicious:days

GlaxoSmithKline, AstraZeneca and other Pharmaceutical Leaders Reduce R&D Time and Costs Using AspenTech’s Software

August 19, 2010

Industry Collaboration Results in Newly Patented Technology that Helps Drug Companies Comply with Latest Regulatory “Quality by Design” Initiatives

Burlington, Mass – July19th, 2010- Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced that GlaxoSmithKline, AstraZeneca and other pharmaceutical industry leaders are reducing their research and development time and costs using newly patented technology that is part of AspenTech’saspenONE Process Development for Pharmaceuticals software.

Supporting Quotes:
Stephen Carino, Investigator – Solid Form Sciences Group, GlaxoSmithKline
“Screening for crystalline forms is an essential component in pharmaceutical drug development. In our high-throughput screening workflow, we have utilized NRTL-SAC in Aspen Properties to predict the equilibrium solubility of the drug in single- and multi-component solvent systems. The predicted solubility values are used in selecting an appropriate set of solvent systems that are explicitly unique for each of the crystallization modes. This rational solvent selection coupled with the systematic screening approach has allowed us to assess risk around solid forms and improve our confidence in the robustness of the API processes.”

Jamie Hintlian, Vice President of Pharmaceuticals, Aspen Technology, Inc.
“Solubility is essential in evaluating drug candidacy and manufacturability. Without predictive tools, many organizations are forced to fly blind when it comes to this mission-critical information. Solubility modeling and prediction adds value by enabling greater efficiencies, better decision making, faster process development, and better process performance. For the pharmaceutical industry leaders involved in its development, and other potential users, this is a powerful screening protocol for the drug development process.”

Supporting Resources:

About AspenTech
AspenTech is a leading supplier of software that optimizes process manufacturing – for energy, chemicals, pharmaceuticals, engineering and construction, and other industries that manufacture and produce products from a chemical process. With integrated aspenONE solutions, process manufacturers can implement best practices for optimizing their engineering, manufacturing and supply chain operations. As a result, AspenTech customers are better able to increase capacity, improve margins, reduce costs and become more energy efficient. To see how the world’s leading process manufacturers rely on AspenTech to achieve their operational excellence goals, visit www.aspentech.com.

Latest News

Health IT Outcomes: Partnership Streamlines Submission of Preadmission Screening Forms

Binding Site Slashes Production Time and Saves Hundreds of Thousands of Dollars with Datawatch Self-Service Data Preparation

Datawatch and Tableau Partner to Speed and Broaden Analytics with Self-Service Data Preparation

Xcede Technologies Announces Collaboration with Cook Biotech Inc.

Finding New Life for Medical Waste. This is not a typical plastics recycling story.

Optics segment continues double digit growth in 2015

A&G Working on New Project with First Citizens Bank

AMP Agency Grows Integrated Media Team with Newly Appointed Leadership Team


Latest Newsletters

April 2016 – Andrew DeLorey joins Mass Capital

March 2016 – Mass Capital announces a new investment in Valet Park of America

January 2016 – Mass Capital announces a new investment in Phillips Screw Company

November 2015 – Mass Capital announces a new investment in Triumvirate Environmental

September 2015 – Mass Capital announces a new investment in MedTouch

September Newsletter 2014

Mass. Capital Announces Addition to Investment Team

January 2014 Newsletter


Archives